All News
SLE uncommonly has ILD in clinical practice. 2% had ILD usually mild and non progressive abstr 1563 #ACR #ACR19 @RheumNow #SLE https://t.co/CWgdfEQZ27
Janet Pope Janetbirdope ( View Tweet)
Prednisone is associated with organ damage in SLE. Chicken or egg argument? Bad lupus gets more steroids and more damage AND steroids independently increase CV events and other damage ex OP and cataracts #ACR19 @RheumNow abstr 2562 #SLE https://t.co/onEII3OKhS
Janet Pope Janetbirdope ( View Tweet)
Abstract #1759 MTX did not demonstrate superior efficacy over placebo on pain and function at 3 and 12 months Erosive Hand OA (EHOA). MTX significantly reduced the progression of joint damage compared to placebo #ACR19 @RheumNow
Do you use MTX in EHOA?
Dr. Antoni Chan synovialjoints ( View Tweet)
A short piece I wrote for @RheumNow on classification criteria and their role in diagnosis / clinical practice
1. These are meant for research!
2. We use them for diagnosis anyway...
3. Remember their limitations when doing so!
@RheumNow
https://t.co/SSr28zkc0U https://t.co/EDzgWPIxXe
Mike Putman EBRheum ( View Tweet)
Great talk by Dr. Manzi for Year in Review!
See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NOT for joints.
@RheumNow #ACR19
https://t.co/FzY8O7KX1A
Mike Putman EBRheum ( View Tweet)
It's Dr. Paul Sufka @psufka talking about methotrexate and prednisone for Hand osteoarthritis https://t.co/jRwWgzVvPx #ACR19 @rheumnow
Philip Robinson philipcrobinson ( View Tweet)
This is an excellent review by @BolekBerqui on the use of social media. Great quote “We can think of the internet like the medical elevator” #ACR19 #ACRBest @RheumNow https://t.co/CNzVtrFgr2
Dr. Antoni Chan synovialjoints ( View Tweet)
BK virus bite Mia was not increased in CTD or drug use. Safe and reassuring and different from cornyviris which is increased with Rituximab but small study. Maybe underpowered #ACR19 @RheumNow abstr 2115 https://t.co/8z77Pxgp3E
Janet Pope Janetbirdope ( View Tweet)
#ACR19 Year in Review: Important trial in APLS this year demonstrating to me that DOACs should clearly not be used in this disease state.
Rate of stroke 19% in rivaroxaban vs. 3% in warfarin. @RheumNow https://t.co/YkXRg0J944
Mike Putman EBRheum ( View Tweet)
#ACR19 Year in Review: Dr. Manzi Re: Medical Cannabis -
"Bottom line is that it's here and our patients are ordering it off Amazon."
This has been my experience as well! Need high quality studies to know the possible risks and benefits @RheumNow https://t.co/k8we1HWfkk
Mike Putman EBRheum ( View Tweet)
Does VTE increase risk of subsequent MACE (cardiac events ie MI). National Data Bank excluded pts with past CV events. 2X risk of future CVE post VTE. Strange as risks are a bit different #ACRbest #ACR19 @RheumNow abst196 https://t.co/XoSkow7AAQ
Janet Pope Janetbirdope ( View Tweet)
Efficacy and Safety of Upadacitinib in a
Randomized, Double-Blind, Placebo-Controlled,
Multicenter Phase 2/3 Clinical Study of Patients With Active AS
• Onset of response to upadacitinib 15 mg QD tx was rapid
• AEs similar between upadacitinib and placebo
#ACR19 @RheumNow
Kanika Monga, MD DrKanikaMonga ( View Tweet)
Abstr#2273: higher placental transfer antiTNFs=ADA,IFX,GOL. Less transfer=CTZ,ETN. No ⬆️ in infxns in offspring, even with 3rd tri exposure. Potential trend for ⬆️ in serious infxns (>/=1 hosp adm 1st yr of life) with high placental transfer antiTNFs, not sig. #ACR2019 @RheumNow https://t.co/qEIl9lxlv1
Maeve Gamble MaeveGamble ( View Tweet)
Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A
ASAS40: a composite measure including patient global, pain, function, and inflammation
In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo
Dr. Deodhar #ACR19 @RheumNow https://t.co/yLwt47w2wr
Jonathan Hausmann MD hausmannMD ( View Tweet)
MYTH: Tocilizumab should be reserved for GCA patients whom prednisone has failed
#PearlsAndMyths Dr. John Stone #ACR19 @RheumNow https://t.co/tVrC5XP0ot
Kanika Monga, MD DrKanikaMonga ( View Tweet)
Interesting withdrawal study of tofacitinib in children with JIA showed that drug was better than placebo at preventing disease flares. #pedirheum #ACR19 @RheumNow https://t.co/lHWNJGmmtF
Jonathan Hausmann MD hausmannMD ( View Tweet)
NEW ANCA Associated Vasculitis Guidelines - discussed at #ACR19
1. Rituxan > cytoxan
2. Reduced steroid regimen!
3. Rec against PLEX
4. Rec FOR scheduled RTX over ANCA+B cell guided
5. MTX for limited dx
Well done everyone - very reasonable and evidence based!
@RheumNow https://t.co/oX6qEJDQON
Mike Putman EBRheum ( View Tweet)
NEW Draft Guidelines for EGPA presented at #ACR19 @RheumNow
1. TTE and FFS to guide tx
2. GC plus cytoxan or rituxan for active/severe dx
3. Imuran/MMF/MTX for maintenance after severe dx
4. Mepo for non-severe over csDMARDs
Larger role for RTX than expected, overall reasonable https://t.co/MEb10n5Mzd
Mike Putman EBRheum ( View Tweet)
Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube
Philip Robinson philipcrobinson ( View Tweet)
Pregnancy outcome in the DESIR cohort (SpA cohort) #ACR19 @RheumNow https://t.co/PcwR6rrMRw
Philip Robinson philipcrobinson ( View Tweet)